CHICAGO--()--Zacks Equity Research highlights Cooper Tire & Rubber Co. (NYSE: CTB) as the Bull of the Day and Citi Trends (Nasdaq: CTRN) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Life Technologies Corporation (Nasdaq: LIFE), MDS Analytical Technologies (NYSE: MDS) and Danaher Corporation (NYSE: DHR).
Full analysis of all these stocks is available at http://at.zacks.com/?id=2676.
Here is a synopsis of all five stocks:
Cooper Tire & Rubber Co. (NYSE: CTB) is well positioned to enjoy improved operating costs, greater geographic flexibility and the ability to penetrate international markets through its investments and facilities in low-cost countries.
The company continues to realize the benefits of reducing costs in its manufacturing operations. It has also been able to absorb the costs associated with the need to curtail production to align with demand.
In the second quarter, Cooper Tire returned to profitability after a year. Earnings increased tenfold compared to the Zacks Consensus Estimate of $0.04. As such, we have upgraded the stock to an Outperform recommendation with a six-month target price of $20 per share.
Citi Trends (Nasdaq: CTRN) is exposed to continuing macroeconomic headwinds, which is adversely affecting its performance. The company recorded a 12.4% decline in same-store sales during fiscal 2009 second quarter, while its store expansion efforts dragged down operating results.
Moreover, intense competition from other off-price retailers, mass merchants and smaller players is exerting immense pressure on the company's profitability. These factors severely undermine the company's future growth prospects and sustainability.
Our recommendation for the company is Underperform, as we anticipate it to perform well below the broader market.
Latest Posts on the Zacks Analyst Blog:
Life Beats, Boosts Outlook
Life Technologies Corporation (Nasdaq: LIFE) reported third quarter earnings of 73 cents per share, well above the Zacks Consensus Estimate of 61 cents. The company reported earnings of 63 cents in the year-ago period.
Strong growth in Europe, Asia-Pacific and Japan helped revenues increase 3% to $805 million. Excluding the impact of currency and the divested LIMS business, revenues grew 5%.
Apart from the Cell Systems division, all other revenue segments at Life recorded an increase in sales. The Molecular Biology Systems division recorded a 5% increase in revenues, which came in at $394 million. Revenues were driven by demand across the portfolio, including continued strong orders for the company’s Influenza A (H1N1)-related products.
Double-digit growth for consumable kits and capillary electrophoresis instruments sold into applied markets like forensics, continued growth of next-generation sequencing systems, as well as low single-digit growth in capillary electrophoresis sold into the life science research market helped boost Genetic Systems revenues, which increased 5% to $216 million.
Cell Systems division revenue declined 3% to $189 million in the third quarter due to declines in media sold to pharmaceutical and biotechnology customers. However, the segment reported significant growth in other product areas such as stem cell-related products and cellular analysis solutions.
The Mass Spectrometry division, which is Life’s joint venture with MDS Analytical Technologies (NYSE: MDS), contributed $6 million in other income, increasing 2% from the year-ago period. Life entered into an agreement in Sept. 2009 under which it will be selling its share in this joint venture to Danaher Corporation (NYSE: DHR) for $450 million. In our view, the sale of this business will allow Life to focus on the high growth molecular and genomics markets.
Get the full analysis of all these stocks by going to http://at.zacks.com/?id=2649.
About the Bull and Bear of the Day
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
About the Analyst Blog
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2677.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Facebook
Twitter
LinkedIn
Delicious
Reddit
StumbleUpon
Digg
MySpace
Newsvine
Google Bookmark
Yahoo! Bookmark
Email
Email 
